PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
- 1 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (7) , 1644-1655
Abstract
Purpose: Immune checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma (MM). Experimental Design: Bone marrow (BM) mononuclear cells were obtained from 77 newly diagnosed MM patients. We examined the expression of immune checkpoint receptors in BM CD8+ T cells and their functional restoration by ex vivo treatment with anti-PD-1 and TGF-b inhibitors. Results: We confirmed the upregulation of PD-1 and PD-L1 expression in CD8+ T cells and myeloma cells, respectively, from the BM of MM patients. PD-1-expressing CD8+ T cells from the BM of MM patients co-expressed other checkpoint inhibitory receptors and exhibited a terminally differentiated phenotype. These results were also observed in BM CD8+ T cells specific to myeloma antigens NY-ESO-1 and HM1.24. BM CD8+ T cells from MM patients exhibited reduced proliferation and cytokine production upon T-cell receptor stimulation. However, anti-PD-1 did not increase the proliferation of BM CD8+ T cells from MM patients, indicating that T-cell exhaustion in MM is hardly reversed by PD-1 blockade alone. Intriguingly, anti-PD-1 significantly increased the proliferation of BM CD8+ T cells from MM patients in the presence of inhibitors of TGF-b, which was overexpressed by myeloma cells. Conclusions: Our findings indicate that combined blockade of PD-1 and TGF-b may be useful for the treatment of MM.Keywords
All Related Versions
Funding Information
- National Research Foundation (NRF-2017R1A2A1A17069782, NRF-2018M3A9D3079498)
- National Research Foundation (NRF-2018R1C1B6008261, NRF-2018M3A9D3079499)
This publication has 47 references indexed in Scilit:
- Robust isolation of malignant plasma cells in multiple myelomaBlood, 2014
- A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic DiseasePLOS ONE, 2012
- Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral InfectionScience, 2012
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myelomaLeukemia, 2012
- MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of SurvivinClinical Cancer Research, 2011
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersJournal of Immunological Methods, 2009
- Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathwayBlood, 2007
- NY-ESO-1 immunotherapy for multiple myelomaLeukemia & Lymphoma, 2006
- Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response.Journal of Clinical Investigation, 1997